Evidence map›Paper›PMID 28625885›Full record

ReviewClinical immunology (Orlando, Fla.)2017

DOCK8 deficiency: Insights into pathophysiology, clinical features and management.

Catherine M Biggs, Sevgi Keles, Talal A Chatila

Open access · greenAbstract readReview
In one paragraph

Review in Clinical immunology (Orlando, Fla.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 3 syntheses or guidelines pooled it, 170 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Emerging Paediatric Uses of Dupilumab Beyond Approvals.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Fungal Infections in Disorders of Inborn Errors of Immunity.Clinical reviews in allergy & immunology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Review
  14. Review
  15. Decreased IL-17-producing TThe journal of allergy and clinical immunology. Global · 2026
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Catherine M BiggsDivision of Immunology, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA, USA; Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
Sevgi KelesDivision of Pediatric Allergy and Immunology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey.
Talal A ChatilaDivision of Immunology, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Electronic address: talal.chatila@childrens.harvard.edu.
Boston Children's Hospital · USNecmettin Erbakan University · TR

Funding

MOLECULAR BASIS OF ALLERGIC AND IMMUNOLOGIC DISEASET32AI007512 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI Janet Chou, Peter A Nigrovic · 1996 to 2026
$13.1M
Molecular Basis of Hyper lgE ImmunodeficiencyR01AI065617 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Talal Amine Chatila · 2006 to 2026
$10.9M
Mechanisms of Disease Pathogenesis in Regulatory T cell DeficiencyR01AI085090 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHATILA, TALAL AMINE, WILLIAMS, CALVIN B · 2010 to 2020
$3.9M
NIAID NIH HHS R01 AI065617NIAID NIH HHS R01 AI085090NIAID NIH HHS T32 AI007512
6 · The paper itself

Abstract

Dedicator of cytokinesis 8 (DOCK8) deficiency is a combined immunodeficiency that exemplifies the broad clinical features of primary immunodeficiencies (PIDs), extending beyond recurrent infections to include atopy, autoimmunity and cancer. It is caused by loss of function mutations in DOCK8, encoding a guanine nucleotide exchange factor highly expressed in lymphocytes that regulates the actin cytoskeleton. Additional roles of DOCK8 have also emerged, including regulating MyD88-dependent Toll-like receptor signaling and the activation of the transcription factor STAT3. DOCK8 deficiency impairs immune cell migration, function and survival, and it impacts both innate and adaptive immune responses. Clinically, DOCK8 deficiency is characterized by allergic inflammation as well as susceptibility towards infections, autoimmunity and malignancy. This review details the pathophysiology, clinical features and management of DOCK8 deficiency. It also surveys the recently discovered combined immunodeficiency due to DOCK2 deficiency, highlighting in the process the emerging spectrum of PIDs resulting from DOCK protein family abnormalities.

Indexed as

Actin CytoskeletonActive Transport, Cell NucleusAdaptive ImmunityAutoimmune DiseasesCell MovementCell SurvivalEczemaEpstein-Barr Virus InfectionsGuanine Nucleotide Exchange FactorsHematopoietic Stem Cell TransplantationHumansHypersensitivityImmunity, InnateImmunologic Deficiency SyndromesInfectionsInflammationDOCK8 protein, humanGuanine Nucleotide Exchange FactorsSTAT3 Transcription FactorActinCDC42Combined immunodeficiencyDedicator of cytokinesisDOCK2DOCK8Hyper IgE syndromePrimary immunodeficiencyRAC1STAT3

Identifiers

PMID28625885
PMCPMC5555255
OpenAlexW2626877998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.